Early Briefing and Review: Accuray Inc., Chelsea Therapeutics Intl. Ltd, ZIOPHARM Oncology Inc., and Antares Pharma Inc.

   Early Briefing and Review: Accuray Inc., Chelsea Therapeutics Intl. Ltd,
               ZIOPHARM Oncology Inc., and Antares Pharma Inc.

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, October 8, 2013

LONDON, October 8, 2013 /PRNewswire/ --

OnMonday, October 7, 2013, all three benchmark indexes of the US equity
market closed lower, with the Dow Jones Industrial Average, the S&P 500, and
the NASDAQ Composite falling by 0.90%, 0.85%, and 0.98%, respectively. Shares
in the healthcare sector ended mostly on a lower note, tracking losses in the
broader market. The major movers included Accuray Inc. (NASDAQ: ARAY),
Chelsea Therapeutics International Ltd (NASDAQ: CHTP), ZIOPHARM Oncology Inc.
(NASDAQ: ZIOP), and Antares Pharma Inc. (NASDAQ: ATRS). AAAResearchReports.com
has released free charting and technical research on these aforementioned
companies. Register to read these reports at:

http://www.aaaresearchreports.com/register/ 

Accuray Inc.'s stock edged higher on Monday, hitting a new 52-week high of
$7.64. The company's shares fluctuated between $7.47 and $7.64 before
finishing the day at $7.61, which is 0.26% higher from its previous closing
price. A total of 0.66 million shares were traded which is below the daily
average volume of 1.09 million. Shares in Accuray Inc. have gained 2.84% in
the last three trading sessions. In the last three months the stock has surged
33.98%, outperforming the S&P 500 which has advanced 2.71% during the same
period. Moreover, Accuray Inc.'s shares are currently trading above their
50-day and 200-day moving averages of $6.56 and $5.49, respectively. Sign up
for free report on ARAY at:

http://www.AAAResearchReports.com/ARAY100813.pdf

Chelsea Therapeutics International Ltd's stock fell on Monday, tracking losses
in the broader market. The company's shares hit an intraday high of $2.94
before finishing the day 1.37% lower at $2.88. A total of 0.64 million shares
were traded which is below the daily average volume of 1.00 million. Shares in
Chelsea Therapeutics International Ltd. have gained 15.20% in the previous
three months, outperforming the S&P 500 which has gained 2.71% during the same
period. Further, Chelsea Therapeutics International Ltd's stock is currently
trading above its 200-day moving average of $2.04. CHTP free technical report
can be accessed by signing up at:

http://www.AAAResearchReports.com/CHTP100813.pdf

On Monday, ZIOPHARM Oncology Inc.'s stock fell, as the broader market edged
lower. The company's shares traded between $4.52 and $4.78 before finishing
the day at $4.60, which is 1.71% lower than its previous day's closing price
of $4.68. A total of 1.29 million shares were traded which is above the daily
average volume of 0.93 million. The company's shares are currently trading
22.69% lower than the 52-week high of $5.95 and 208.72% higher than 52-week
low of $1.490. Shares of the company have gained 8.75% in the previous three
trading sessions. In the last three months the stock has rallied 88.52%,
outperforming the S&P 500 which has advanced 2.71% during the same period.
Additionally, ZIOPHARM Oncology Inc.'s shares are currently trading above
their 50-day and 200-day moving averages of $3.24 and $3.13, respectively. A
free report on ZIOP can be accessed by registering at:

http://www.AAAResearchReports.com/ZIOP100813.pdf

Antares Pharma Inc.'s stock fell on Monday, after posting gains in the
previous trading session. The company's shares hit an intraday high of $4.66
before finishing the day 1.31% lower at $4.53. A total of 1.88 million shares
were traded which is above the daily average volume of 1.02 million. Shares of
Antares Pharma Inc. have gained 5.84% in the last three sessions. Moreover,
Antares Pharma Inc.'s stock is currently trading above its 50-day and 200-day
moving averages of $4.35 and $3.99, respectively. Register with AAA Research
Reports and download research on ATRS for free at:

http://www.AAAResearchReports.com/ATRS100813.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: Peter F. Jones; +1(646)396-9126 (North America);
info@aaaresearchreports.com